Plasma long-chain omega-3 fatty acids and atrophy of the medial temporal lobe

Objective: The long-chain ω-3 fatty acids eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) are potential candidates for interventions to delay Alzheimer disease (AD), but evidence from clinical studies is mixed. We aimed at determining whether plasma levels of EPA or DHA predict atrophy of medial temporal lobe (MTL) gray matter regions in older subjects. Methods: A total of 281 community dwellers from the Three-City Study, aged 65 years or older, had plasma fatty acid measurements at baseline and underwent MRI examinations at baseline and at 4 years. We studied the association between plasma EPA and DHA and MTL gray matter volume change at 4 years. Results: Higher plasma EPA, but not DHA, was associated with lower gray matter atrophy of the right hippocampal/parahippocampal area and of the right amygdala (p < 0.05, familywise error corrected). Based on a mean right amygdala volume loss of 6.0 mm3/y (0.6%), a 1 SD higher plasma EPA (+0.64% of total plasma fatty acids) at baseline was related to a 1.3 mm3 smaller gray matter loss per year in the right amygdala. Higher atrophy of the right amygdala was associated with greater 4-year decline in semantic memory performances and more depressive symptoms. Conclusion: The amygdala, which develops neuropathology in the early stage of AD and is involved in the pathogenesis of depression, may be an important brain structure involved in the association between EPA and cognitive decline and depressive symptoms.

[1]  C. DeCarli,et al.  Red blood cell omega-3 fatty acid levels and markers of accelerated brain aging , 2012, Neurology.

[2]  H. Amièva,et al.  Omega-3 fatty acids and cognitive decline: modulation by ApoEε4 allele and depression , 2011, Neurobiology of Aging.

[3]  H. Jacqmin-Gadda,et al.  Misuse of the linear mixed model when evaluating risk factors of cognitive decline. , 2011, American journal of epidemiology.

[4]  G. Busatto,et al.  Neurostructural predictors of Alzheimer's disease: A meta-analysis of VBM studies , 2011, Neurobiology of Aging.

[5]  J. Kaye,et al.  Nutrient biomarker patterns, cognitive function, and MRI measures of brain aging , 2011, Neurology.

[6]  Alzheimer's Disease Neuroimaging Initiative,et al.  Six-month atrophy in MTL structures is associated with subsequent memory decline in elderly controls , 2010, NeuroImage.

[7]  Geert Molenberghs,et al.  Random Effects Models for Longitudinal Data , 2010 .

[8]  Michael Weiner,et al.  Docosahexaenoic acid supplementation and cognitive decline in Alzheimer disease: a randomized trial. , 2010, JAMA.

[9]  A. Blackwell,et al.  Beneficial effects of docosahexaenoic acid on cognition in age-related cognitive decline , 2010, Alzheimer's & Dementia.

[10]  Marcus Richards,et al.  Effect of 2-y n-3 long-chain polyunsaturated fatty acid supplementation on cognitive function in older people: a randomized, double-blind, controlled trial. , 2010, The American journal of clinical nutrition.

[11]  Pienie Zwitserlood,et al.  Automatic Mood-Congruent Amygdala Responses to Masked Facial Expressions in Major Depression , 2010, Biological Psychiatry.

[12]  Siegfried Kasper,et al.  Area-specific modulation of neural activation comparing escitalopram and citalopram revealed by pharmaco-fMRI: A randomized cross-over study , 2010, NeuroImage.

[13]  J. Martins.  EPA but Not DHA Appears To Be Responsible for the Efficacy of Omega-3 Long Chain Polyunsaturated Fatty Acid Supplementation in Depression: Evidence from a Meta-Analysis of Randomized Controlled Trials , 2009, Journal of the American College of Nutrition.

[14]  P. Barberger-Gateau,et al.  Fish, docosahexaenoic acid and Alzheimer's disease. , 2009, Progress in lipid research.

[15]  Li Shen,et al.  Baseline MRI Predictors of Conversion from MCI to Probable AD in the ADNI Cohort , 2009, Current Alzheimer research.

[16]  K. Yaffe,et al.  Fish consumption, long-chain omega-3 fatty acids and risk of cognitive decline or Alzheimer disease: a complex association , 2009, Nature Clinical Practice Neurology.

[17]  H. Amièva,et al.  Prodromal Alzheimer's disease: Successive emergence of the clinical symptoms , 2008, Annals of neurology.

[18]  Eric J. Nestler,et al.  The molecular neurobiology of depression , 2008, Nature.

[19]  P. Barberger‐Gateau,et al.  Low plasma eicosapentaenoic acid and depressive symptomatology are independent predictors of dementia risk. , 2008, The American journal of clinical nutrition.

[20]  B. Fielding,et al.  Fatty acid composition of adipose tissue and blood in humans and its use as a biomarker of dietary intake. , 2008, Progress in lipid research.

[21]  D. Mozaffarian,et al.  Fish consumption and risk of subclinical brain abnormalities on MRI in older adults , 2008, Neurology.

[22]  J. P. Hamilton,et al.  Amygdala volume in major depressive disorder: a meta-analysis of magnetic resonance imaging studies , 2008, Molecular Psychiatry.

[23]  P. Barberger‐Gateau,et al.  Plasma eicosapentaenoic acid is inversely associated with severity of depressive symptomatology in the elderly: data from the Bordeaux sample of the Three-City Study. , 2008, The American journal of clinical nutrition.

[24]  A. Hariri,et al.  Long-chain omega-3 fatty acid intake is associated positively with corticolimbic gray matter volume in healthy adults , 2007, Neuroscience Letters.

[25]  Jakub Hort,et al.  Magnetic resonance analysis of amygdalar volume in Alzheimer's disease , 2007, Current opinion in psychiatry.

[26]  V. Salomaa,et al.  Non-participation and mortality in different socioeconomic groups: the FINRISK population surveys in 1972–92 , 2007, Journal of Epidemiology and Community Health.

[27]  Hélène Jacqmin-Gadda,et al.  A Nonlinear Model with Latent Process for Cognitive Evolution Using Multivariate Longitudinal Data , 2006, Biometrics.

[28]  M. Morris.  Docosahexaenoic acid and Alzheimer disease. , 2006, Archives of neurology.

[29]  G. Parker,et al.  Omega-3 fatty acids and mood disorders. , 2006, The American journal of psychiatry.

[30]  S. Leurgans,et al.  MRI predictors of risk of incident Alzheimer disease , 2005, Neurology.

[31]  Carole Dufouil,et al.  No ɛ4 gene dose effect on hippocampal atrophy in a large MRI database of healthy elderly subjects , 2005, NeuroImage.

[32]  R. Holman,et al.  Vascular Factors and Risk of Dementia: Design of the Three-City Study and Baseline Characteristics of the Study Population , 2003, Neuroepidemiology.

[33]  N. Tzourio-Mazoyer,et al.  Automated Anatomical Labeling of Activations in SPM Using a Macroscopic Anatomical Parcellation of the MNI MRI Single-Subject Brain , 2002, NeuroImage.

[34]  D H Freeman,et al.  Depressive symptoms in relation to physical health and functioning in the elderly. , 1986, American journal of epidemiology.

[35]  J. Ware,et al.  Random-effects models for longitudinal data. , 1982, Biometrics.

[36]  S. Folstein,et al.  “Mini-mental state”: A practical method for grading the cognitive state of patients for the clinician , 1975 .

[37]  B Isaacs,et al.  The Set Test as an Aid to the Detection of Dementia in Old People , 1973, British Journal of Psychiatry.

[38]  A. Hofman,et al.  Use of hippocampal and amygdalar volumes on magnetic resonance imaging to predict dementia in cognitively intact elderly people. , 2006, Archives of general psychiatry.

[39]  Carole Dufouil,et al.  No epsilon4 gene dose effect on hippocampal atrophy in a large MRI database of healthy elderly subjects. , 2005, NeuroImage.

[40]  R. Hu.  Diagnostic and Statistical Manual of Mental Disorders (DSM-IV) , 2003 .

[41]  F. Rouillon,et al.  La version française de l'échelle CES-D (Center for Epidemiologic Studies-Depression Scale). Description et traduction de l'échelle d'autoévaluation. , 1989 .

[42]  Á. Száz.  Minimal structures , generalized topologies , and ascending systems should not be studied without generalized uniformities , 2007 .

[43]  L. Radloff.  The CES-D Scale: A Self-Report Depression Scale for Research in the General Population — Source link , 2022 .